Dr Reddy’s launches two new semaglutide brands amid Obeda supply disruptions
The drugmaker has shifted production to a partner facility and expects to resolve the impurity issue affecting its injectable product next month.
The drugmaker has shifted production to a partner facility and expects to resolve the impurity issue affecting its injectable product next month.
Business Line - Home
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗